XR Securities’s Intellia Therapeutics NTLA Stock Holding History

XR Securities’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-4,304	Closed	-$234K	–	542
2020 Q4	$234K	Buy	+4,304	New	+$156K	0.02%	179

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

XR Securities's NTLA Position: Q1 2021 in Review

XR Securities sold out of Intellia Therapeutics (NTLA) in Q1 2021, closing a stake of 4,304 shares — an estimated $234K sold.

XR Securities first reported a position in NTLA in Q4 2020 and held it in 1 quarter. The position peaked at $234K in Q4 2020. 260 funds tracked by Wall St. Rank hold NTLA as of Q1 2021.

XR Securities reported no remaining Intellia Therapeutics position as of Q1 2021 after selling out during the quarter.
XR Securities sold 4,304 Intellia Therapeutics shares in Q1 2021, an estimated $234K.
XR Securities first reported a position in Intellia Therapeutics in Q4 2020 and held it in 1 quarter.
XR Securities's Intellia Therapeutics position peaked at $234K in Q4 2020.
260 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2021.

Based on XR Securities's 13F filing for Q1 2021, filed 29 Apr 2021.